Pharmaceutical

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and

REPLY: Go Reply and Sprint Reply Automate the Creation of Clinical Study Re

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Coll

Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2

Allurion Announces Closing of Offering and Concurrent Private Placement to

Element Unveils AVITI24™ Innovation Roadmap Ahead of the Advances in Geno

BioTech Breakthrough Awards BostonGene With “Cancer Immunology Solution o

Zoetis to Participate in Upcoming Investor Conferences

Vector Laboratories Announces Partnership With British Biotech Innovator Et

Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Fo

Board of Eigenmann & Veronelli Welcomes Two New Independent Directors to Su

Lantern Pharma Announces PCT Patent Application Publication for Innovative,

Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pi

Chewy Announces Participation in the Morgan Stanley Technology, Media & Tel

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with

Enpro Reports Fourth Quarter and Full Year 2024 Results, Introduces 2025 Gu

GoodRx Achieves HITRUST i1 Certification to Manage Data Protection and Miti

Quantum-Si’s Customers and Researchers to Showcase Next-Generation Protei

Cegeka Launches Microsoft Dynamics Practice for Americas Pharmaceutical and

NationsBenefits® Expands Retail Network with Walgreens, Leveraging Innovat

Bruker Reports Fourth Quarter and Full Year 2024 Financial Results